Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19)

NCT04988217 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

173

Enrollment

OTHER

Sponsor class

Conditions

Coronavirus Disease 2019

Interventions

DRUG: Interferon-Alpha2B
DRUG: Placebo

Sponsor

Pontificia Universidad Catolica de Chile

Collaborators

[object Object]